Molecular biology in acute leukemia

Clinical and Translational Oncology

Volumn 8, Issue 8, 2006, Pages 550-559

  Camós, Mireia ^a   Colomer, Dolors ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Acute lymphoblastic leukemia; Acute myeloid leukemia; Molecular biology

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; CD135 ANTIGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; ECOCOTROPIC VIRUS INTEGRATION SITE 1 PROTEIN; HYBRID PROTEIN; K RAS PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; MYC PROTEIN; MYOSIN HEAVY CHAIN; MYST3 PROTEIN; NOTCH1 RECEPTOR; NUCLEOPHOSMIN; ONCOPROTEIN; PROTEIN DERIVATIVE; PROTEIN TYROSINE KINASE; RAS PROTEIN; RETINOIC ACID RECEPTOR ALPHA; STAT5 PROTEIN; STEM CELL FACTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR DELTA CHAIN; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR HOXA10; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR RUNX1; ZINC FINGER PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; BLAST CELL; CANCER CLASSIFICATION; CELL LINEAGE; CHROMOSOME 12P; CHROMOSOME 16P; CHROMOSOME 16Q; CHROMOSOME 19P; CHROMOSOME 1Q; CHROMOSOME 21Q; CHROMOSOME 22Q; CHROMOSOME 8P; CHROMOSOME 8Q; CHROMOSOME 9Q; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 12; CHROMOSOME TRANSLOCATION 16; CHROMOSOME TRANSLOCATION 19; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 8; CHROMOSOME TRANSLOCATION 9; GENE REARRANGEMENT; HUMAN; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; ONCOGENE; PROMYELOCYTIC LEUKEMIA; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; ACUTE DISEASE; CHROMOSOME ABERRATION; GENETICS; MUTATION; MYELOID LEUKEMIA; REVIEW;

ACUTE DISEASE; CHROMOSOME ABERRATIONS; GENE REARRANGEMENT; HUMANS; LEUKEMIA, MYELOID; MUTATION; ONCOGENE PROTEINS, FUSION; SIGNAL TRANSDUCTION;

EID: 33749041690     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0060-6     Document Type: Article

References (72)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051-62.
2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-55.
3. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18:115-36.
4. Frohling, S, Scholl, G, Gilliand DG, Levine, RL. Genetics of myeloid malignancies: Pathogenetic and clinical implications. J Clin Oncol. 2005;25:6285-95.
5. Mrozek K, Heinonen K, Bloomfield CD, Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14:19-47.
6. Blyth K, Cameron ER, Neil JC. The RUNX genes: Gain or loss of function in cancer. Nat Rev Cancer. 2005;5:576-87.
7. Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001;27:265-70.
8. Linggi, B, Mull-Tidow G, Pavan de LL, et al. The t(8l;21) fusion protein, AML1 ETO, specifically represses the transcription of the P14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med. 2002;8:743-50.
9. Durst KL, Lutterbach B, Kummalue T, Friedman AD, Hiebert SW. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavychain domain. Mol Cell Biol. 2005;25:607-19.
10. Kanno Y, Kanno T, Sakakura C, Bae SC, Ito Y Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBF alpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits. Mol Cell Biol. 1998;18:4252-61.
11. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;95:5167-215.
12. Pandolfi PP. In vivo analysis of the molecular genetics of acute promyelocytic leukemia. Oncogene. 2001;20:5726-55.
13. Sun T, Wu E. Acute monoblastic leukemia with t(8;16): A distinct clinicopathologic entity; report of a case and review of the literature. Am J Hematol. 2001;66:207-12.
14. Borrow J, Stanton VP, Jr., Andresen JM, et al. The translocation t(8;16)(p11;13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet. 1996;14:33-41.
15. Champagne N, Pelletier N, Yang XJ. The monocytic leukemia zinc finger protein MOZ is a histone acetyltransferase. Oncogene. 2001;20:404-9.
16. Rozman M, Camos M, Colomer D, et al. Type 1 MOZ/CBP (MYST5/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11; p13) translocation. Genes Chromosomes Cancer. 2004;40:140-5.
17. Kitabayashi I, Aikawa Y, Nguyen LA, Yokoyama A, Ohki M. Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. EMBO J. 2001;20:7184-96.
18. Allard S, Masson JY, Cote J. Chromatin remodeling and the maintenance of genome integrity. Biochim. Biophys Acta. 2004;1677:158-64.
19. Kitabayashi I, Aikawa Y, Yokoyama A, et al. Fusion of MOZ and p500 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q15) chromosome translocation. Leukemia. 2001;15:89-94.
20. Liang J, Prouty L, Williams BJ, Dayton MA, Blanchard KL. Acute mixed lineage leukemia with an inv(8)(p11q15) resulting in fusion of the genes for MOZ and TIF2, Blood 1998;92:2118-22.
21. Panagopoulos I, Fioretos T, Isaksson M, et al. Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16) (q22;p15). Hum Mol Genet. 2001;10:395-404.
22. Rowley JD, Reshmi S, Sobulo O, et al All patients with the T(11;16)(q25;p13.3) that involves MLL and GBP have treatment-related hematologic disorders. Blood. 1997; 90;555-41.
23. Camos M, Esteve J, Jares P, et al. Gene Expression Profiling of Acute Myeloid Leukemia with Translocation t(8;16)(p11;p15) and MYST5-CREBBP Rearrangement Reveals a Distinctive Signature with a Specific Pattern of HOX Gene Expression. Cancer Res. 2006;66:6947-54.
24. Leroy H, Roumier C, Huyghe P, Biggio V, Fenaux P, Preudhomme C. CEBPA point mutations in hematological malignancies. Leukemia. 2005;19:529-54.
25. Frohling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22:624-55.
26. Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (AL-FA). Blood. 2002;100:2717-25.
27. Steffen B, Muller-Tidow C, Schwable J, Berdel WE, Serve H. The molecular pathogenesis of acute myeloid leukemia. Crit Rev Oncol Hematol. 2005;56:195-221.
28. Satake N, Maseki N, Nishiyama M, et al. Chromosome abnormalities and MLL rearrangements in acute myeloid leukemia of infants. Leukemia. 1999;15:1013-7.
29. Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q25/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood. 2005;102:2395-402.
30. Steudel C, Wermke M, Schaich M, et al. Comparative analysis of MLL partial tandem duplication and FLT5 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer. 2003;37:237-51.
31. Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia. 2000;14:796-804.
32. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;550:1617-28.
33. Armstrong SA, Stauton JE, Silverman LB, et al. MLL translocation specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30:41-7.
34. Naoe T, Kiyoi H. Normal and oncogenic FLT3. Cell Mol Life Sci. 2004;61:2952-8.
35. Moreno I, Martin G, Bolufer P, et al. Incidence and prognostic value of FLT3 internal tandem duplication and D855 mutations in acute myeloid leukemia. Haematologica. 2005;88:19-24.
36. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT5 length mutation im 1005 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100:59-66.
37. Brandts CH, Sargin B, Rode M, et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res. 2005;65:9643-50.
38. Radomska HS, Basseres DS, Zheng R, et al. Block of C/EBP alpha function by phosphorylation in acute function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med. 2006;205:571-81.
39. Tickenbrock L, Schwable J, Wiedehage M, et al. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood. 2005; 105:5699-706.
40. Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2005;121:775-7.
41. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT5 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;95:3074-80
42. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer. 2006;6:493-505.
43. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254-66.
44. Falini B, Martelli MP, Bolli N, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood. 2006 (pub ahead).
45. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006; 107:4011-4020.
46. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 2005;23:6306-15.
47. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004; 350:1535-48.
48. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1:133-45.
49. Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2005;5:175-85.
50. Taketani T, Taki T, Sugita K, et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood. 2004;103:1085-8.
51. Sigvardsson M. Overlapping expression of early B-cell factor and basic helix-loop-helix proteins as a mechanisms to dictate B-lineage-specific activity of the lambda5 promoter Mol Cell Biol. 2000;20:5640-54.
52. Wong S, Witte ON. The BCR-ABL story: Bench to bedside and back. Annu Rev Immunol. 2004;22:247-306.
53. Hubeek I, Stam RW, Peters GJ, et al. The human equilibrative nucleoside transporter 1 mediatesitro cytarabine sensitivity in childhood acute myeloid leukemia. Br J Cancer. 2003;93:1588-94.
54. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2006;6:547-59.
55. Baer R. TaL1, TAL2 and LYL1: A family of basic helix-loop-helix proteins implicated in T cell acute leukaemia. Semin Cancer Biol. 1993;4:341-7.
56. Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH. The rhombotin family of cysteine-rich LIM-domain oncogenes: Distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p15. Proc Natl Acad Sci USA. 1991;88:4367-71.
57. Abramovich C, Humphries RK. Hox regulation of normal and leukemic hematopoietic stem cells. Curr Opin Hematol. 2005;12:210-6.
58. Rothenberg EV, Taghon T. Molecular genetics of T cell development. Annu Rev. Immunol. 2005;23:601-49.
59. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1:75-87.
60. Soulier J, Clappier E, Cayuela JM, et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood. 2005; 106:274-86.
61. Ferrando AA, Look AT. Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol. 2003;40:274-80.
62. Asnafi V, Radford-Weiss I, Dastugue N, et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. Blood. 2003;102:1000-6.
63. Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: From thymocyte to lymphoblast. Leukemia, 2006.
64. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309-12.
65. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269-71.
66. Omura-Minamisawa M, Diccianni MB, Batova A, et al. Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2000;6:1219-28.
67. Pabst T, Mueller BU, Harakawa N, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med. 2001; 7:444-51.
68. Schoch C, Haferlach T. Cytogenetics in acute myeloid leukemia. Curr Oncol Rep. 2002;4:390-7.
69. Libura M, Asnafi V, Tu A, et al. FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. Blood. 2003;102:2198-204.
70. Ozeki K, Kiyoi H, Hirose Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood. 2004;103:1901-8.
71. Wieser R. Rearrangements of chromosome band 3q21 in myeloid leukemia. Leuk Lymphoma. 2002;45:59-65.
72. Ferrando AA, Armstrong SA, Neuberg DS, et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: Dominance of HOX dysregulation. Blood. 2005;102:262-8.